FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891483775> ?p ?o ?g. }

• W2891483775 abstract "e18250 Background: Bevacizumab (Bev) can be associated with clinically significant bleeding. Patients (pts) in community practice have increased comorbidities, leading to some reluctance to use Bev with anticoagulation (AC) or antiplatelet therapy (APT). This study was conducted to determine the incidence of Bev induced bleeding in colorectal (CRC) and non-colorectal (non-CRC) cancer pts in a real-world setting. Methods: In this retrospective analysis, pts with Bev treated CRC and non-CRC from Jan 2010 to Jan 2017 at our hospital were identified. Bleeding was graded according to CTCAE v4.0. Chi-Square and ANOVA were used to calculate associations. Overall survival (OS) and progression free survival (PFS) were calculated using Kaplan-Meier and log rank methods. Results: 241 pts were evaluated (mean age = 63; 54% females), 112 with CRC and 129 with non-CRC (lung = 27%; gynecologic = 14%; CNS = 7%; other = 5%). Median duration of Bev therapy was 21 weeks. Overall bleeding was 22% (mucocutaneous = 14%; hematochezia = 4.5%; hematemesis = 1%; hematuria 2.5%; cerebral hemorrhage = 1%). Grade 3 bleeding occurred in 8 pts (epistaxis = 1; hematemesis = 2; hematochezia = 1; hematuria = 4), of whom 1 was on AC. There were no grade > 3 events. Concomitant AC (n = 35) increased bleeding risk ( p = 0.01) whereas APT (n = 43) did not ( p = 0.4). There was no association of bleeding and Bev dose ( p = 0.1); however, longer duration of therapy increased bleeding risk ( p = 0.01). In CRC pts, concomitant chemotherapy (oxaliplatin vs irinotecan), bleeding history, intact tumors and tumor side were not associated with increased risk ( p > 0.05). In CRC, pts with bleeding had longer estimated median OS (52 [95%CI, 35-66] vs 35 [95%CI, 22-48] months; p= 0.079) and PFS (80 [95%CI, 59-101] vs 72 [95%CI, 49-95] months; p= 0.048). Conclusions: We demonstrated in a modern community hospital practice that there is a 22% incidence of bleeding with Bev, although mostly mild even with concurrent AC, and only 3% grade 3. Concurrent AC but not APT was associated with increased bleeding risk and warrants careful discussion with pts. The observation of longer OS and PFS in pts with Bev induced bleeding warrants further investigation." @default.
• W2891483775 created "2018-09-27" @default.
• W2891483775 creator A5007528796 @default.
• W2891483775 creator A5021336796 @default.
• W2891483775 creator A5029815253 @default.
• W2891483775 creator A5045473392 @default.
• W2891483775 creator A5057352789 @default.
• W2891483775 creator A5065303026 @default.
• W2891483775 creator A5065431287 @default.
• W2891483775 creator A5088826153 @default.
• W2891483775 date "2017-05-20" @default.
• W2891483775 modified "2023-09-27" @default.
• W2891483775 title "Bevacizumab-induced bleeding in colorectal and noncolorectal cancer patients in a community oncology setting: An Abington Memorial Hospital experience." @default.
• W2891483775 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18250" @default.
• W2891483775 hasPublicationYear "2017" @default.
• W2891483775 type Work @default.
• W2891483775 sameAs 2891483775 @default.
• W2891483775 citedByCount "1" @default.
• W2891483775 countsByYear W28914837752017 @default.
• W2891483775 crossrefType "journal-article" @default.
• W2891483775 hasAuthorship W2891483775A5007528796 @default.
• W2891483775 hasAuthorship W2891483775A5021336796 @default.
• W2891483775 hasAuthorship W2891483775A5029815253 @default.
• W2891483775 hasAuthorship W2891483775A5045473392 @default.
• W2891483775 hasAuthorship W2891483775A5057352789 @default.
• W2891483775 hasAuthorship W2891483775A5065303026 @default.
• W2891483775 hasAuthorship W2891483775A5065431287 @default.
• W2891483775 hasAuthorship W2891483775A5088826153 @default.
• W2891483775 hasConcept C121608353 @default.
• W2891483775 hasConcept C126322002 @default.
• W2891483775 hasConcept C143998085 @default.
• W2891483775 hasConcept C2776694085 @default.
• W2891483775 hasConcept C2777802072 @default.
• W2891483775 hasConcept C526805850 @default.
• W2891483775 hasConcept C61434518 @default.
• W2891483775 hasConcept C71924100 @default.
• W2891483775 hasConceptScore W2891483775C121608353 @default.
• W2891483775 hasConceptScore W2891483775C126322002 @default.
• W2891483775 hasConceptScore W2891483775C143998085 @default.
• W2891483775 hasConceptScore W2891483775C2776694085 @default.
• W2891483775 hasConceptScore W2891483775C2777802072 @default.
• W2891483775 hasConceptScore W2891483775C526805850 @default.
• W2891483775 hasConceptScore W2891483775C61434518 @default.
• W2891483775 hasConceptScore W2891483775C71924100 @default.
• W2891483775 hasLocation W28914837751 @default.
• W2891483775 hasOpenAccess W2891483775 @default.
• W2891483775 hasPrimaryLocation W28914837751 @default.
• W2891483775 hasRelatedWork W1975661080 @default.
• W2891483775 hasRelatedWork W1988706862 @default.
• W2891483775 hasRelatedWork W1996010439 @default.
• W2891483775 hasRelatedWork W2034172836 @default.
• W2891483775 hasRelatedWork W2089857502 @default.
• W2891483775 hasRelatedWork W2100460633 @default.
• W2891483775 hasRelatedWork W2132798780 @default.
• W2891483775 hasRelatedWork W2242319010 @default.
• W2891483775 hasRelatedWork W2287618579 @default.
• W2891483775 hasRelatedWork W2546154929 @default.
• W2891483775 hasRelatedWork W2589795422 @default.
• W2891483775 hasRelatedWork W2764139177 @default.
• W2891483775 hasRelatedWork W2913000593 @default.
• W2891483775 hasRelatedWork W3027618744 @default.
• W2891483775 hasRelatedWork W3094292764 @default.
• W2891483775 hasRelatedWork W3107641981 @default.
• W2891483775 hasRelatedWork W3196870482 @default.
• W2891483775 hasRelatedWork W3201612254 @default.
• W2891483775 hasRelatedWork W1817246953 @default.
• W2891483775 hasRelatedWork W2953174923 @default.
• W2891483775 isParatext "false" @default.
• W2891483775 isRetracted "false" @default.
• W2891483775 magId "2891483775" @default.
• W2891483775 workType "article" @default.